Review article about the PI3K inhibitor copanlisib against B cell malignancies

What is it about?

We set out to highlight the commonalities and differences of copanlisib and idelalisib, two PI3K inhibitors with recognized potential for treatment of B cell malignancies. Our review starts from the molecular structure activity relationships and isoform specificities and, via the impact on diverse cell functions, leads to administration schemes, adverse effect profiles and clinical efficacies.

Featured Image

Why is it important?

This compilation of the properties of copanlisib in comparison with idelalisib for a multidisciplinary audience aims to convey current mechanistic understanding of the PI3K signaling hub as a drug target for the treatment of B cell malignancies.